Cargando…
Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway‐related proteins
Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐related fatalities worldwide. Identification of second‐line therapies for patients with progressive HCC is urgently required as the use of sorafenib and/or regorafenib remains unsatisfactory. Imatinib, a small‐molecule kinase inhibi...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931239/ https://www.ncbi.nlm.nih.gov/pubmed/33289342 http://dx.doi.org/10.1002/2211-5463.13052 |